Jia Liu: IBI343 Advances from Early-Phase Research to Positive Phase 3 Results in Gastric Cancer

Jia Liu, Medical oncologist at The Kinghorn Cancer Centre, shared on X: “From presenting Phase 1 data at ESMOGI24 to Nature Medicine publication in 2025 to seeing positive Phase 3 results from G-HOPE-001 in CLDN18.2 positive 3L+ G/GEJA presented by Kohei Shitara at ESMO26! Wonderful to have been part of the development journey of arcotatug tavatecan (IBI343), a CLDN18.2-targeting ADC! OS HR 0.57 (10.2 vs 6.9 mo) PFS HR 0.45 (7.1 vs 3.1 mo) Grade ≥3 treatment-related AEs: 47.4% vs 55.9%; dose reductions: 17.8% vs 35.1% compared with chemotherapy. Congratulations to all investigators and the Innovent and Takeda teams! Looking forward to exploring rational combinations to further improve patient outcomes!” More thoroughly about the importance of phase 1 trial on gastroesophageal junction adenocarcinoma  The study investigates IBI343, a CLDN18.2-targeting antibody drug conjugate (ADC), as a potential treatment for advanced gastric and gastroesophageal junction adenocarcinoma, where effective options remain limited, particularly in later treatment lines. In this Phase 1 trial, IBI343 achieved a confirmed objective response rate of 29% and median progression-free survival of 5.5 months among patients with high CLDN18.2 expression treated at the recommended Phase 2 dose of 6 mg/kg. The findings reinforce the importance of measuring CLDN18.2 expression
Read More